{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.questionFirstAnswered.=2019-10-21T15%3A40%3A50.25Z&min-date=2019-10-16&AnsweringBody.=Department+of+Health+and+Social+Care&tablingMemberConstituency=North+East+Hampshire&max-date=2019-12-20", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.questionFirstAnswered.=2019-10-21T15%3A40%3A50.25Z&min-date=2019-10-16&AnsweringBody.=Department+of+Health+and+Social+Care&tablingMemberConstituency=North+East+Hampshire&max-date=2019-12-20", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.questionFirstAnswered.=2019-10-21T15%3A40%3A50.25Z&min-date=2019-10-16&AnsweringBody.=Department+of+Health+and+Social+Care&tablingMemberConstituency=North+East+Hampshire&max-date=2019-12-20&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.questionFirstAnswered.=2019-10-21T15%3A40%3A50.25Z&_page=0&min-date=2019-10-16&AnsweringBody.=Department+of+Health+and+Social+Care&tablingMemberConstituency=North+East+Hampshire&max-date=2019-12-20", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.questionFirstAnswered.=2019-10-21T15%3A40%3A50.25Z&min-date=2019-10-16&AnsweringBody.=Department+of+Health+and+Social+Care&tablingMemberConstituency=North+East+Hampshire&max-date=2019-12-20", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.questionFirstAnswered.=2019-10-21T15%3A40%3A50.25Z&min-date=2019-10-16&AnsweringBody.=Department+of+Health+and+Social+Care&tablingMemberConstituency=North+East+Hampshire&max-date=2019-12-20", "items" : [{"_about" : "http://data.parliament.uk/resources/1150221", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1150221/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors the safety of all medicines on the market in the United Kingdom. Following a recent European review of the available epidemiological data on the risk of neurodevelopmental disorders with use of paracetamol in pregnancy, the product information for paracetamol is already being updated to reflect the findings.<\/p><p>The MHRA has sought independent advice from its expert committees on this latest study which found an increased risk of neurocognitive effects in children born to women who took paracetamol during pregnancy. The expert committees advised that the new study adds to the existing body of evidence but does not provide any further insight into a possible causal association between in utero exposure to paracetamol and neurodevelopmental outcomes.<\/p><p>Patients should be advised that if necessary, paracetamol can be used during pregnancy. However, it should be used at the lowest possible dose that reduces symptoms and for the shortest time possible.<\/p><p>Pregnant women should speak to their doctor or midwife before taking any medicine, including paracetamol.<\/p><p> <\/p><p> <\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"}
        , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"}
        , "dateOfAnswer" : {"_value" : "2019-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-10-21T15:40:50.25Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-10-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Epidemiology: Paediatrics"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his Department's policies of the research by the University of Bristol published on 16 September 2019 in Paediatric and Perinatal Epidemiology; and whether he plans update his Department's guidance as a result of that research.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
      }
      , "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
      ], "uin" : "1075"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}